Factors Linked to Worse CAR-T Outcomes in High-Risk Multiple Myeloma

by | Mar 9, 2023 | Myeloma News | 0 comments

Source: Myeloma – Hematology Advisor

High-risk cytogenetics and extramedullary disease may be associated with worse survival outcomes of CAR T-cell therapy in relapsed or refractory multiple myeloma, a meta-analysis suggests.
Read More

Submit a Comment